AssetMark Inc’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.05M Sell
53,738
-621
-1% -$15.2K ﹤0.01% 1032
2025
Q4
$1.46M Sell
54,359
-2,128
-4% -$54.8K ﹤0.01% 933
2025
Q3
$1.51M Buy
56,487
+12,721
+29% +$328K ﹤0.01% 891
2025
Q2
$1M Buy
43,766
+3,229
+8% +$80.1K ﹤0.01% 922
2025
Q1
$1.18M Sell
40,537
-1,384
-3% -$44.2K ﹤0.01% 837
2024
Q4
$1.56M Sell
41,921
-1,985
-5% -$90.8K ﹤0.01% 764
2024
Q3
$2.13M Buy
43,906
+3,650
+9% +$160K 0.01% 637
2024
Q2
$1.61M Buy
40,256
+4,479
+13% +$186K 0.01% 666
2024
Q1
$1.57M Sell
35,777
-10
-0% -$516 0.01% 632
2023
Q4
$2.21M Buy
35,787
+4,596
+15% +$241K 0.01% 518
2023
Q3
$1.43M Buy
31,191
+94
+0.3% +$5.13K 0.01% 560
2023
Q2
$1.79M Buy
31,097
+1,424
+5% +$63.1K 0.01% 500
2023
Q1
$1.11M Buy
29,673
+1,727
+6% +$56.6K ﹤0.01% 581
2022
Q4
$783K Buy
27,946
+1,814
+7% +$52.7K ﹤0.01% 635
2022
Q3
$734K Buy
+26,132
New +$853K ﹤0.01% 586
2018
Q1
Sell
-11
Closed 1421
2017
Q4
$0 Buy
+11
New +$205 ﹤0.01% 1858
2017
Q1
Sell
-5
Closed 1265
2016
Q4
$0 Buy
+5
New +$97 ﹤0.01% 1240

Other funds holding AMPH

AssetMark Inc's AMPH Position: Q1 2026 in Review

AssetMark Inc reduced its Amphastar Pharmaceuticals (AMPH) stake by 1.1% in Q1 2026, selling an estimated $15.2K and leaving 53,738 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1032.

AssetMark Inc first reported a position in AMPH in Q4 2016 and has held it in 17 quarters since. The position peaked at $2.21M in Q4 2023. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • AssetMark Inc held 53,738 shares of Amphastar Pharmaceuticals worth $1.05M as of Q1 2026.
  • AssetMark Inc sold 621 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $15.2K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #1032 holding.
  • AssetMark Inc first reported a position in Amphastar Pharmaceuticals in Q4 2016 and has held it in 17 quarters since.
  • AssetMark Inc's Amphastar Pharmaceuticals position peaked at $2.21M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.